ES2080788T3 - Cicloalcanos heterociclicos utiles como inhibidores de 5-lipoxigenasa. - Google Patents

Cicloalcanos heterociclicos utiles como inhibidores de 5-lipoxigenasa.

Info

Publication number
ES2080788T3
ES2080788T3 ES90301935T ES90301935T ES2080788T3 ES 2080788 T3 ES2080788 T3 ES 2080788T3 ES 90301935 T ES90301935 T ES 90301935T ES 90301935 T ES90301935 T ES 90301935T ES 2080788 T3 ES2080788 T3 ES 2080788T3
Authority
ES
Spain
Prior art keywords
hetero
alkylene
cyclic
cycloalcans
substitutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90301935T
Other languages
English (en)
Inventor
Graham Charles Crawley
Jean-Marc Marie Mauri Girodeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca SAS
Syngenta Ltd
Original Assignee
Zeneca Pharma SA
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Pharma SA, Zeneca Ltd filed Critical Zeneca Pharma SA
Application granted granted Critical
Publication of ES2080788T3 publication Critical patent/ES2080788T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Communication System (AREA)
  • Electroluminescent Light Sources (AREA)
  • Buildings Adapted To Withstand Abnormal External Influences (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)

Abstract

EL INVENTO SE REFIERE A UN CICLOALKANO HETEROCICLICO DE LA FORMULA (I) DONDE Q ES UNA MOLECULA HETEROCICLICA BICICLICA DE 10 MIEMBROS O MONOCICLICA DE 6 MIEMBROS SUSTITUIDA QUE CONTIENE 1 O 2 ATOMOS DE NITROGENO; A ES ALKILENO C1-6, ALKENILENO C3-6, ALKINILENO C3-6, O CICLOALKILENO C3-6; X ES OXI, TIO, SULFINIL, SULFONIL O IMINO; AR ES FENILENO QUE PUEDE SOPORTAR OPCIONALMENTE 1 O 2 SUSTITUYENTES O AR ES UNA MOLECULA DE HETEROCICLENO DE 6 MIEMBROS QUE CONTIENE MAS DE TRES ATOMOS DE NITROGENO; R1 ES HIDROGENO, ALKIL C1-6, ALKENIL C3-6, ALKINIL C3-6, CIANOALKIL C1-4, O ALKANOIL C2-4, U OPCIONALMENTE BENZOIL SUSTITUIDO; R2 Y R3 JUNTAS FORMAN UN GRUPO ALKILENO C3-6 QUE JUNTO CON EL ATOMO DE CARBONO AL CUAL R2 Y R3 ESTAN SUJETAS, DEFINE UN ANILLO QUE TIENE ENTRE 4 Y 7 ATOMOS, Y QUE PUEDE SOPORTAR UNO O DOS SUTITUYENTES, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO. LOS COMPUESTOS DEL INVENTO SON INHIBIDORES DE LA ENZIMA 5-LIPOXIGENASA.
ES90301935T 1989-02-28 1990-02-22 Cicloalcanos heterociclicos utiles como inhibidores de 5-lipoxigenasa. Expired - Lifetime ES2080788T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP89400559 1989-02-28

Publications (1)

Publication Number Publication Date
ES2080788T3 true ES2080788T3 (es) 1996-02-16

Family

ID=8202930

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90301935T Expired - Lifetime ES2080788T3 (es) 1989-02-28 1990-02-22 Cicloalcanos heterociclicos utiles como inhibidores de 5-lipoxigenasa.

Country Status (15)

Country Link
EP (1) EP0385663B1 (es)
JP (1) JP2851353B2 (es)
AT (1) ATE131158T1 (es)
AU (1) AU626989B2 (es)
CA (1) CA2010211A1 (es)
DE (1) DE69023940T2 (es)
DK (1) DK0385663T3 (es)
ES (1) ES2080788T3 (es)
FI (1) FI901009A7 (es)
GR (1) GR3018316T3 (es)
IL (1) IL93343A0 (es)
NO (1) NO900917L (es)
NZ (1) NZ232514A (es)
PT (1) PT93288A (es)
ZA (1) ZA901042B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089495A (en) * 1989-01-30 1992-02-18 Imperial Chemical Industries Plc Heterocyclic thiazole derivatives and pharmaceutical compositions comprising said derivatives
IE70521B1 (en) * 1989-02-28 1996-12-11 Zeneca Pharma Sa Heterocycles with inhibitory activity of 5-lipoxygenase
IE911919A1 (en) * 1990-06-21 1992-01-01 Zeneca Ltd Bicyclic heterocyclic compounds
US5281720A (en) * 1991-02-28 1994-01-25 Merck Frosst Canada, Inc. Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis
US5227399A (en) * 1991-02-28 1993-07-13 Merck Frosst Canada, Inc. Pyranylphenyl naphthalene lactones as inhibitors of leukotriene biosynthesis
EP0505122A1 (en) * 1991-03-21 1992-09-23 Zeneca Limited Alpha, alpha-dialkylbenzyl derivatives
EP0570112A1 (en) * 1992-04-23 1993-11-18 Zeneca Limited Cycloalkane derivatives
US5308852A (en) * 1992-06-29 1994-05-03 Merck Frosst Canada, Inc. Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
US5268379A (en) * 1992-08-24 1993-12-07 Abbott Laboratories Ether-containing inhibitors of 5-lipoxygenase
US5426109A (en) * 1992-08-27 1995-06-20 Merck Frosst Canada, Inc. Phenylnaphthalene hydroxy acids
US5252599A (en) * 1992-08-27 1993-10-12 Merck Frosst Canada, Inc. Heteroarylnaphthalene hydroxy acids as inhibitors of leukotriene biosynthesis
US5428060A (en) * 1992-08-27 1995-06-27 Merck Frosst Canada, Inc. Heteroarylnaphthalene lactones as inhibitors of leukotriene biosynthesis
US5350744A (en) * 1992-08-27 1994-09-27 Merck Frosst Canada, Inc. Phenylnaphthalene lactones as inhibitors of leukotriene biosynthesis
WO1994005638A1 (en) * 1992-09-02 1994-03-17 Abbott Laboratories Trans 1,4-diether cyclohexane inhibitors of 5-lipoxygenase
US5407959A (en) * 1993-11-12 1995-04-18 Abbott Laboratories (Trans-1,4-dialkoxycyclohexyl) substituted arylalkylaryl-arylalkenylaryl-, and arylalkynylarylurea inhibitors of 5-lipoxygenase
US5446062A (en) * 1993-11-12 1995-08-29 Abbott Laboratories ((4-alkoxypyran-4-yl) substituted) ether, arylalkyl-, arylalkenyl-, and arylalkynyl)urea inhibitors of 5-lipoxygenase
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6548670B1 (en) 2001-07-19 2003-04-15 Air Products And Chemicals, Inc. Methods for preparing 5- and 6-benzyl-functionalized quinoxalines
US6825221B2 (en) 2001-10-18 2004-11-30 Allergan, Inc. Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
WO2007087250A2 (en) * 2006-01-23 2007-08-02 Amira Pharmaceuticals, Inc. Tricyclic inhibitors of 5-lipoxygenase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO174506B (no) * 1984-10-30 1994-02-07 Usv Pharma Corp Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser
US4661596A (en) * 1985-02-21 1987-04-28 American Home Products Corporation Quinolinyl (or pyridinyl) methoxy substituted naphthalene compounds as antiallergic agents
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
DE3617183A1 (de) * 1985-11-16 1987-05-27 Bayer Ag Substituierte benzylether
IL93344A0 (en) * 1989-02-28 1990-11-29 Ici Plc Heterocyclic cyclic ethers
IE70521B1 (en) * 1989-02-28 1996-12-11 Zeneca Pharma Sa Heterocycles with inhibitory activity of 5-lipoxygenase
IE66512B1 (en) * 1989-02-28 1996-01-10 Ici Plc Heterocyclic ethers as 5-lipoxygenase inhibitors

Also Published As

Publication number Publication date
JPH02268158A (ja) 1990-11-01
NZ232514A (en) 1992-04-28
JP2851353B2 (ja) 1999-01-27
DK0385663T3 (da) 1996-03-11
FI901009A0 (fi) 1990-02-28
GR3018316T3 (en) 1996-03-31
DE69023940T2 (de) 1996-04-25
FI901009A7 (fi) 1990-08-29
PT93288A (pt) 1990-08-31
EP0385663A3 (en) 1991-11-21
IL93343A0 (en) 1990-11-29
NO900917L (no) 1990-08-29
CA2010211A1 (en) 1990-08-31
AU626989B2 (en) 1992-08-13
DE69023940D1 (de) 1996-01-18
AU4976490A (en) 1990-09-06
EP0385663A2 (en) 1990-09-05
ATE131158T1 (de) 1995-12-15
ZA901042B (en) 1990-10-31
NO900917D0 (no) 1990-02-27
EP0385663B1 (en) 1995-12-06

Similar Documents

Publication Publication Date Title
ES2085330T3 (es) Eteres ciclicos heterociclicos con actividad inhibidora de 5-lipoxigenasa.
ES2058809T3 (es) Derivados heterociclicos.
ES2080900T3 (es) Derivados piranicos utiles como inhibidores de 5-lipoxigenasa.
ES2062051T3 (es) Derivados heterociclicos.
PE18095A1 (es) 3-bencilaminometil piperidinas sustituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
AR011660A1 (es) Uso de un compuesto neurotrofico de sulfonamida para efectuar una actividad neuronal en un animal
ES2062052T3 (es) Derivados de cicloalcanos.
CO4950557A1 (es) Compuestos y metodos
NO20040407L (no) Metoder for a mobilisere progenitor/stamceller.
AR011882A1 (es) Derivados de n-oxidos de esteres, amidas, tioesteres y cetonas heterociclicas, composicion farmaceutica y uso del compuesto.
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
ES2061502T3 (es) Nuevos n-heterociclos biciclicos puenteados.
ES2127912T3 (es) Benzoderivados condensados.
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
MX9700871A (es) Procedimiento para hacer compuestos antimicrobianos.
ES8306750A1 (es) Un procedimiento para la preparacion de 2-guanidino-4-heteroariltiazoles.
AU8981991A (en) Novel amino and nitro containing tricyclic compounds useful as inhibitors of ace
ES2123812T3 (es) Derivados 1,5-benzodiazepina utiles como antagonistas de las cck o de la gastrina.
CO4480026A1 (es) Nuevos compuestos que inhiben la accion de la lipoxigenasa y composiciones farmaceuticas que los contienen . . .
DK0696585T3 (da) Nyt bisoxadiazolidinderivat
EA200101230A1 (ru) Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции
PE20030611A1 (es) Compuestos basicos lineales que tienen actividad antagonista de nk-2 y sus formulaciones
ES2145306T3 (es) Nitro-benzamidas utiles como agentes anti-arritmicos.
ES2074142T3 (es) Compuestos heterociclicos.
SE8303913L (sv) Heterocykliska foreningar

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 385663

Country of ref document: ES